PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-24.09%
Both companies show declining cash positions (-24.09% vs AVXL's -18.61%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-24.09%
Cash + STI yoy 1.25-1.5x AVXL's -18.61%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.04%
Similar yoy growth to AVXL's -18.75%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-17.11%
0.5-0.75x AVXL's -32.98%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.78%
Below half of AVXL's -32.98%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Similar yoy to AVXL's -18.75%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
86.42%
Less than half of AVXL's -12.18%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Above 1.5x AVXL's -0.29%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of AVXL's 398.15%. Michael Burry suspects a big gap in pre-sales traction.
-55.20%
Less than half of AVXL's 398.15%. David Dodd sees fewer expansions in other current obligations.
21.67%
Less than half of AVXL's -10.66%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.67%
Less than half of AVXL's -10.66%. David Dodd sees far fewer liability expansions relative to competitor.
0.96%
Above 1.5x AVXL's 0.04%. Michael Burry suspects heavy new equity expansion or dilution.
-5.35%
≥ 1.5x AVXL's -3.23%. David Dodd sees higher yoy retained profits than competitor.
-15.38%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
1.25-1.5x AVXL's -20.78%. Bruce Berkowitz notes an above-average equity expansion.
-19.98%
Similar yoy to AVXL's -18.75%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AVXL's -0.28%. Michael Burry sees a major jump. Investigate leverage rationale.
23.76%
1.25-1.5x AVXL's 18.74%. Martin Whitman is wary of heavier net leverage vs. competitor.